

Date: June 7, 2017

Dr. Jindrich Kopecek
cc: Paul Shami, MD, Jiyuan Yang, PhD

RE: FY18 ET Award

Dear Dr. Kopecek:

We are pleased to officially notify you that you have been awarded a grant from the Experimental Therapeutics Program (ET) to support your research project. Funding from the ET Program is provided by the Huntsman Cancer Institute with the goal of promoting transdisciplinary, collaborative research that will impact our understanding of cancer.

Award Number: 180303

Project Title: Albumin-Based Combination Therapeutics for Treatment of B-cell Lymphomas

Awarded Amount: \$40,000

Earliest Possible Funding Start Date: July 1, 2017

This funding comes with the expectation that it will support collaborative research resulting in published manuscripts and grant submission to the National Cancer Institute (NCI). The award is intended to provide funding for innovative projects that can be completed within one year of the transfer of funds. Extension of funds (at most, for one year) and/or future grants are contingent on compliance with keeping us up-to-date on these outcomes, which are very important to the success of the Cancer Center Support Grant.

We will request a brief progress report summarizing your results, collaborative interactions, and future plans twice yearly. A final report will be requested 60 days after the end of the funding period. In addition, we typically ask that all awardees present a progress report of their project at one of our Program meetings. We will contact you biannually to track outcomes for some time after this project in order to report successes to NCI.

A few additional logistical items are as follows:

- Please remember that manuscripts resulting, even in part, from this funding should contain the following statement: “We acknowledge support of funds in conjunction with grant P30 CA042014 awarded to Huntsman Cancer Institute and to the ET Program at Huntsman Cancer Institute.”
 - However, please do not associate the manuscript with the CCSG grant within the National Institutes of Health Manuscript Submission (NIHMS) or My Bibliography. While this award is made in conjunction with the CCSG, it is not directly funded by the CCSG; as such, NIH public access policy is not applicable to this context.
- It is expected that you will have the appropriate approvals (i.e. IRB, IACUC, and Biosafety) before starting work on this project. Kristi Smith from HCI Research Administration will contact you regarding IRB and IACUC details. Kevin Cheney from HCI Finance will assist in setting up accounts, and will transfer award funding after the appropriate protocol approvals are in place.


- You are responsible for financial accounting of how project funds were spent. The award should be used for research activities and cannot be used for faculty salary support or for the purchase of large equipment. Funding can be used for salaries and fringe benefits of post-doctoral fellows, students, technicians, and other non-faculty project personnel costs. Lab supplies and other related research non-personnel expenses are appropriate but not allowed is travel, office furniture and equipment (including computers).
- You are expected to actively participate in ET Program and Cancer Center activities such as seminars, meetings, and retreats.
- The award must remain solely with the designated awardee and cannot be transferred to any other personnel or institution. Unused funds will be returned to HCI.
- If there are any substantive changes to your experimental plan, please inform us prior to using these funds.

Congratulations again, and we look forward to hearing how the project progresses!

Sincerely,



Martin McMahon, PhD
Co-Leaders, ET Program
Huntsman Cancer Institute



Sunil Sharma, MBA, MD, FACP

By signing below, the award recipient agrees to adhere to the expectations and requirements outlined above.

Jindrich Kopecek, PhD